MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.
MicroRNA (miRNA)
alternative mRNA splicing (AS)
chemotherapy
drug resistance
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
02 Dec 2021
02 Dec 2021
Historique:
received:
04
10
2021
revised:
24
11
2021
accepted:
29
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Cancer is a multifaceted disease that involves several molecular mechanisms including changes in gene expression. Two important processes altered in cancer that lead to changes in gene expression include altered microRNA (miRNA) expression and aberrant splicing events. MiRNAs are short non-coding RNAs that play a central role in regulating RNA silencing and gene expression. Alternative splicing increases the diversity of the proteome by producing several different spliced mRNAs from a single gene for translation. MiRNA expression and alternative splicing events are rigorously regulated processes. Dysregulation of miRNA and splicing events promote carcinogenesis and drug resistance in cancers including breast, cervical, prostate, colorectal, ovarian and leukemia. Alternative splicing may change the target mRNA 3'UTR binding site. This alteration can affect the produced protein and may ultimately affect the drug affinity of target proteins, eventually leading to drug resistance. Drug resistance can be caused by intrinsic and extrinsic factors. The interplay between miRNA and alternative splicing is largely due to splicing resulting in altered 3'UTR targeted binding of miRNAs. This can result in the altered targeting of these isoforms and altered drug targets and drug resistance. Furthermore, the increasing prevalence of cancer drug resistance poses a substantial challenge in the management of the disease. Henceforth, molecular alterations have become highly attractive drug targets to reverse the aberrant effects of miRNAs and splicing events that promote malignancy and drug resistance. While the miRNA-mRNA splicing interplay in cancer drug resistance remains largely to be elucidated, this review focuses on miRNA and alternative mRNA splicing (AS) events in breast, cervical, prostate, colorectal and ovarian cancer, as well as leukemia, and the role these events play in drug resistance. MiRNA induced cancer drug resistance; alternative mRNA splicing (AS) in cancer drug resistance; the interplay between AS and miRNA in chemoresistance will be discussed. Despite this great potential, the interplay between aberrant splicing events and miRNA is understudied but holds great potential in deciphering miRNA-mediated drug resistance.
Identifiants
pubmed: 34944633
pii: biomedicines9121818
doi: 10.3390/biomedicines9121818
pmc: PMC8698559
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : South African Medical Research Council
ID : N/A
Références
Mol Oncol. 2015 Jan;9(1):167-78
pubmed: 25224594
Oncogene. 2003 Oct 20;22(47):7512-23
pubmed: 14576855
J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8
pubmed: 24168967
Cancer Cell Int. 2020 Jul 30;20:355
pubmed: 32760222
Gynecol Oncol. 2012 Feb;124(2):325-34
pubmed: 22005523
Oncogene. 2014 Feb 27;33(9):1082-92
pubmed: 23435423
Cancer Sci. 2019 Feb;110(2):662-673
pubmed: 30485589
Blood. 2016 Oct 13;128(15):1944-1958
pubmed: 27540013
Asian J Urol. 2020 Jul;7(3):233-250
pubmed: 32742925
Oncogenesis. 2016 Feb 15;5:e197
pubmed: 26878391
EMBO Mol Med. 2016 Feb 09;8(3):268-87
pubmed: 26881967
Stem Cells. 2011 Nov;29(11):1661-71
pubmed: 21948564
Oncol Rep. 2018 Mar;39(3):1532-1540
pubmed: 29399698
Cancer Lett. 2014 Oct 28;353(2):201-10
pubmed: 25063739
Cancer Res. 2008 Jan 15;68(2):425-33
pubmed: 18199536
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Gene. 2019 Apr 15;692:35-43
pubmed: 30639603
Int J Breast Cancer. 2013;2013:137414
pubmed: 23864953
N Engl J Med. 2009 Sep 24;361(13):1235-48
pubmed: 19776405
Anticancer Drugs. 2014 Aug;25(7):799-809
pubmed: 24686007
Eur Rev Med Pharmacol Sci. 2016 Nov;20(22):4710-4718
pubmed: 27906431
Mol Cancer Ther. 2015 Aug;14(8):1884-95
pubmed: 26056150
Bioengineered. 2021 Dec;12(1):2203-2213
pubmed: 34082653
Oncogenesis. 2013 Mar 25;2:e40
pubmed: 23552883
Cancer Lett. 2012 Apr 28;317(2):184-91
pubmed: 22120675
Breast Cancer Res Treat. 2015 Jun;151(2):269-80
pubmed: 25900794
J Biol Chem. 2007 Jan 26;282(4):2130-4
pubmed: 17135268
Ann Surg Oncol. 2012 Sep;19(9):3065-71
pubmed: 22322955
Oncol Rep. 2014 Feb;31(2):910-8
pubmed: 24317363
Commun Biol. 2020 May 27;3(1):268
pubmed: 32461560
Leukemia. 2021 Apr;35(4):1108-1120
pubmed: 32753690
BMB Rep. 2014 May;47(5):268-73
pubmed: 24286315
Cancer Res. 2019 Oct 15;79(20):5204-5217
pubmed: 31431456
Am J Cancer Res. 2020 Jan 01;10(1):38-59
pubmed: 32064152
J Cell Biochem. 2018 Jul;119(7):6024-6032
pubmed: 29630744
Cancer Res. 1984 Sep;44(9):3643-53
pubmed: 6744284
Medicine (Baltimore). 2019 Jul;98(30):e16421
pubmed: 31348242
Cell Death Differ. 2018 Feb;25(2):406-420
pubmed: 29125598
Cell Death Dis. 2016 Nov 10;7(11):e2463
pubmed: 27831559
Cancer Med. 2017 Dec;6(12):2897-2908
pubmed: 29125238
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154
pubmed: 31647101
Breast Cancer Res Treat. 2012 Jan;131(2):445-54
pubmed: 21399894
Mol Cancer. 2017 Jul 19;16(1):128
pubmed: 28724435
PLoS One. 2013 Apr 16;8(4):e61858
pubmed: 23613955
Gynecol Oncol. 2014 Mar;132(3):739-44
pubmed: 24472409
PLoS One. 2012;7(11):e50469
pubmed: 23209748
Arch Pharm Res. 2015 Feb;38(2):239-48
pubmed: 25502560
Cancer Sci. 2005 Feb;96(2):111-5
pubmed: 15723655
Epigenetics. 2021 May 30;:1-24
pubmed: 34057028
Mol Cell Biol. 2009 Jul;29(13):3783-90
pubmed: 19414598
Drug Resist Updat. 2020 Dec;53:100728
pubmed: 33070093
Cancer Lett. 2015 Jan 28;356(2 Pt B):597-605
pubmed: 25305453
Oncol Lett. 2016 Dec;12(6):4983-4990
pubmed: 28105205
FEBS J. 2014 Oct;281(20):4718-30
pubmed: 25156775
Oncotarget. 2017 May 23;8(32):53017-53027
pubmed: 28881790
N Engl J Med. 2008 Dec 18;359(25):2641-50
pubmed: 19092150
Cancer Cell Int. 2015 Jul 15;15:71
pubmed: 26180516
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
J Cell Biochem. 2014 Apr;115(4):772-84
pubmed: 24249161
Leukemia. 2014 Jan;28(1):98-107
pubmed: 23974981
Annu Rev Biochem. 2003;72:291-336
pubmed: 12626338
J Gastrointest Oncol. 2015 Apr;6(2):185-200
pubmed: 25830038
Am J Cancer Res. 2020 May 01;10(5):1568-1591
pubmed: 32509398
Pharmacogenomics J. 2009 Feb;9(1):1-13
pubmed: 19156160
J Clin Oncol. 2015 Jul 1;33(19):2129-35
pubmed: 25732161
Nat Genet. 2013 Apr;45(4):385-91, 391e1-2
pubmed: 23535732
Oncogenesis. 2013 Oct 07;2:e75
pubmed: 24100610
Mol Cell Biochem. 2011 Apr;350(1-2):207-13
pubmed: 21197560
Cell Biochem Funct. 2018 Jun;36(4):194-202
pubmed: 29653464
Cancer Res. 2012 Aug 15;72(16):4037-46
pubmed: 22761336
Cell Mol Life Sci. 2019 Feb;76(3):441-451
pubmed: 30374521
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Oncotarget. 2017 Mar 28;8(13):22003-22013
pubmed: 28423543
Methods Mol Biol. 2017;1509:1-10
pubmed: 27826912
Curr Drug Targets. 2015;16(12):1381-403
pubmed: 25808651
Sci Rep. 2017 Feb 06;7:41942
pubmed: 28165066
Ann Transl Med. 2015 Dec;3(21):332
pubmed: 26734642
Immunopharmacol Immunotoxicol. 2012 Dec;34(6):1020-7
pubmed: 22686587
Oncogene. 2016 Apr 21;35(16):2031-9
pubmed: 26234680
Nat Methods. 2010 Dec;7(12):1009-15
pubmed: 21057496
Nature. 2010 Oct 21;467(7318):986-90
pubmed: 20962848
Prostate. 2012 Jul 1;72(10):1093-103
pubmed: 22127852
Am J Pathol. 2012 Jun;180(6):2490-503
pubmed: 22521303
Nat Commun. 2018 Dec 19;9(1):5378
pubmed: 30568163
Tumour Biol. 2015 Sep;36(9):6725-32
pubmed: 25833695
Cancer Res. 2014 Dec 15;74(24):7573-82
pubmed: 25368020
Int J Cancer. 2014 Sep 15;135(6):1286-96
pubmed: 24510775
Oncotarget. 2017 Mar 28;8(13):21719-21732
pubmed: 28423513
Nat Commun. 2021 Jul 9;12(1):4230
pubmed: 34244494
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818809997
pubmed: 30384806
Curr Protein Pept Sci. 2015;16(4):310-5
pubmed: 25929865
Oncol Lett. 2016 Sep;12(3):1737-1744
pubmed: 27602108
Sci Rep. 2013;3:1942
pubmed: 23735886
Prz Gastroenterol. 2019;14(2):89-103
pubmed: 31616522
Mol Cancer Ther. 2012 Dec;11(12):2556-65
pubmed: 23074172
Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):217-25
pubmed: 21242194
Trends Biochem Sci. 2004 Feb;29(2):88-94
pubmed: 15102435
J Cell Physiol. 2019 Apr;234(4):3180-3191
pubmed: 28628227
J Biol Chem. 2010 Jun 18;285(25):19076-84
pubmed: 20406806
J Am Chem Soc. 2018 Mar 28;140(12):4244-4252
pubmed: 29504396
Cancer Cell. 2010 Oct 19;18(4):303-15
pubmed: 20951941
Mutat Res. 2002 Jun 19;503(1-2):37-42
pubmed: 12052501
Onco Targets Ther. 2018 Mar 19;11:1529-1541
pubmed: 29593419
EMBO Mol Med. 2012 Feb;4(2):78-92
pubmed: 22180294
Clin Epigenetics. 2019 Feb 11;11(1):25
pubmed: 30744689
PLoS One. 2013 Jul 05;8(7):e67591
pubmed: 23861775
Cell Physiol Biochem. 2017;41(5):1981-1992
pubmed: 28478444
Biol Chem. 2017 Jul 26;398(8):929-938
pubmed: 28095367
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819828709
pubmed: 30786836
Mol Cell Biol. 2008 Nov;28(22):6773-84
pubmed: 18794355
Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20828-33
pubmed: 21079000
Cell Physiol Biochem. 2013;32(5):1225-37
pubmed: 24335172
Oncotarget. 2015 Oct 13;6(31):31944-57
pubmed: 26397135
Cancer Lett. 2017 Feb 1;386:168-178
pubmed: 27887917
J Biol Chem. 2014 Jan 3;289(1):122-32
pubmed: 24220032
Leuk Res. 2016 Feb;41:62-70
pubmed: 26725775
Ann N Y Acad Sci. 2017 Aug;1401(1):19-27
pubmed: 28891091
Oncol Rep. 2013 Aug;30(2):877-89
pubmed: 23760062
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Invest New Drugs. 2020 Aug;38(4):922-933
pubmed: 31414268
Cancer Gene Ther. 2010 Aug;17(8):523-31
pubmed: 20467450
Int J Clin Exp Pathol. 2015 Mar 01;8(3):2392-9
pubmed: 26045746
Genome Biol. 2018 Mar 23;19(1):40
pubmed: 29571299
Oncotarget. 2020 Nov 17;11(46):4338-4357
pubmed: 33245725
Oncotarget. 2014 Feb 28;5(4):944-58
pubmed: 24659709
World J Gastroenterol. 2018 Sep 14;24(34):3834-3848
pubmed: 30228778
Cell Death Dis. 2016 Dec 22;7(12):e2525
pubmed: 28005075
PLoS One. 2012;7(4):e34210
pubmed: 22523546
Nucleic Acids Res. 2020 Mar 18;48(5):2676-2693
pubmed: 31943118
Tumour Biol. 2014 Dec;35(12):12369-78
pubmed: 25179844
FEBS Lett. 2013 Mar 1;587(5):488-95
pubmed: 23337879
J Biol Chem. 2007 Jul 6;282(27):19410-7
pubmed: 17488725
Oncotarget. 2013 Sep;4(9):1399-415
pubmed: 24009080
Minerva Endocrinol. 2019 Dec;44(4):410-413
pubmed: 31359748
Mol Oncol. 2014 Feb;8(1):83-92
pubmed: 24145123
Br J Cancer. 2013 Jul 23;109(2):452-61
pubmed: 23807165
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Mol Cell. 2011 Feb 18;41(4):371-83
pubmed: 21329876
FEBS Lett. 2007 Mar 20;581(6):1081-6
pubmed: 17320082
Mol Med. 2011;17(11-12):1233-41
pubmed: 21826373
Cell Discov. 2017 Sep 12;3:17029
pubmed: 28904816
Int J Mol Sci. 2017 Nov 26;18(12):
pubmed: 29186860
Oncotarget. 2016 Mar 1;7(9):9951-63
pubmed: 26848861
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Science. 2016 Jun 17;352(6292):1413-6
pubmed: 27313038
PLoS One. 2009 Dec 23;4(12):e8419
pubmed: 20037631
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261614
Cancer Cell Int. 2013 Nov 27;13(1):118
pubmed: 24283459
Oncol Lett. 2014 Jan;7(1):183-188
pubmed: 24348845
Biomolecules. 2019 Jan 10;9(1):
pubmed: 30634681
Mol Cancer. 2011 Sep 01;10:108
pubmed: 21880154
Cancer Chemother Pharmacol. 2017 May;79(5):1003-1011
pubmed: 28391353
Acta Biochim Biophys Sin (Shanghai). 2013 Feb;45(2):80-6
pubmed: 23178914
Clin Colorectal Cancer. 2019 Dec;18(4):e370-e384
pubmed: 31402291
Pharmacogenet Genomics. 2012 Mar;22(3):198-205
pubmed: 22241070
Oncol Rep. 2015 Feb;33(2):607-14
pubmed: 25482885
Nature. 2002 Jul 11;418(6894):236-43
pubmed: 12110900
Hum Genet. 2003 Nov;113(6):551-4
pubmed: 13680360
Int J Oncol. 2018 Oct;53(4):1601-1612
pubmed: 30066905
Prostate. 2010 Oct 1;70(14):1501-12
pubmed: 20687223
J Oncol. 2010;2010:821717
pubmed: 20049172
Genes (Basel). 2021 Jul 18;12(7):
pubmed: 34356101
FEBS Lett. 2012 May 7;586(9):1279-86
pubmed: 22465665
Clin Cancer Res. 2021 May 15;27(10):2848-2860
pubmed: 33674272
Int J Cancer. 2014 Sep 15;135(6):1356-68
pubmed: 24615544
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9237
pubmed: 33015758
Mol Carcinog. 2013 Jan;52(1):70-8
pubmed: 22121083
Nat Rev Clin Oncol. 2013 Oct;10(10):571-87
pubmed: 23999218
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
J Cell Biochem. 2018 Jun;119(6):4945-4956
pubmed: 29384218
Int J Cancer. 2012 Apr 15;130(8):1787-97
pubmed: 21618519
Diabetologia. 2017 Jun;60(6):1057-1065
pubmed: 28280903
Breast Cancer Res Treat. 2012 Jun;133(3):937-47
pubmed: 22094936
Curr Opin Genet Dev. 2018 Feb;48:16-21
pubmed: 29080552
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920947342
pubmed: 32922521
PLoS Comput Biol. 2010 Jul 01;6:e1000832
pubmed: 20617199
J Biol Chem. 2011 Feb 11;286(6):4150-64
pubmed: 21118818
Bioorg Med Chem. 2020 Oct 15;28(20):115712
pubmed: 33069070
Curr Drug Metab. 2009 Oct;10(8):836-41
pubmed: 20214578
Cancers (Basel). 2018 Nov 20;10(11):
pubmed: 30463359
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2820-2829
pubmed: 31293179
Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5269-5279
pubmed: 32086391
Wiley Interdiscip Rev RNA. 2014 Jul-Aug;5(4):445-59
pubmed: 24523246
J Biol Chem. 2012 Feb 3;287(6):4148-56
pubmed: 22157765
BMC Med. 2015 Aug 17;13:195
pubmed: 26278220
Blood. 2015 Feb 19;125(8):1302-13
pubmed: 25515961
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Commun. 2015 Jan 14;6:6042
pubmed: 25586593
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Oncol Rep. 2012 Aug;28(2):592-600
pubmed: 22614869
Mol Cancer Ther. 2009 May;8(5):1055-66
pubmed: 19435871
Clin Exp Metastasis. 2018 Apr;35(4):309-318
pubmed: 29799080
Mol Cancer. 2014 Mar 24;13:71
pubmed: 24655723
Leukemia. 2012 May;26(5):1137-40
pubmed: 22064355
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5593-601
pubmed: 25480548
Nature. 2008 Sep 4;455(7209):64-71
pubmed: 18668037
J Biol Chem. 2016 Aug 12;291(33):17405-16
pubmed: 27330076
Braz J Med Biol Res. 2014 Jan;47(1):60-9
pubmed: 24519092
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21098-103
pubmed: 21078976
Cancer Res. 2019 Oct 15;79(20):5151-5158
pubmed: 31416845
Blood. 2002 Feb 15;99(4):1373-80
pubmed: 11830489
J Theor Biol. 2018 Oct 7;454:253-267
pubmed: 29909142
Am J Med Genet. 1998 Nov 2;80(2):140-4
pubmed: 9805131
Gynecol Oncol. 2007 May;105(2):299-303
pubmed: 17303230
Hum Mutat. 2003 Jan;21(1):101-2
pubmed: 12497643
Neurology. 2011 Sep 6;77(10):987-95
pubmed: 21865574
Nat Rev Genet. 2015 Jul;16(7):421-33
pubmed: 26077373
Leuk Res. 2017 Jun;57:55-56
pubmed: 28288324
Cancer Manag Res. 2020 Oct 09;12:9869-9882
pubmed: 33116845
Science. 2008 Jun 20;320(5883):1643-7
pubmed: 18566288
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4842-4849
pubmed: 31210317
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W202-8
pubmed: 19458158